ADAG
AdageneBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The April 2026 company release improved the story: Adagene reported a 29% ORR in the 20 mg/kg cohort, manageable tolerability, enrollment ahead of plan, and cash runway into early 2028. If 2026 combination updates and the 1H 2027 randomized readout confirm durability, the market can justify a higher probability of a registrational path.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Clinical-stage cash burn keeps dilution risk alive if partnerships, data timing, or trial expansion slip.
Momentum
94
Value
41
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.25 · Bull $7.50 · Bear $1.70
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $8.00
Why
Momentum94 · Δ7d -
Value41 · Δ7d -0.1
Sentiment45 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
94
26% active weight
Current posture
7d trendFlat
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
45
34% active weight
Current posture
7d trendImproving
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 94.2 / Value 41.1 / Sentiment 45.1
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$171.54M
Beta
0.72
Shares Out
47.39M
P/E (TTM) · Derived
-9.7
P/S (TTM)
812.92
P/FCF (TTM) · Derived
-10.87
Rev YoY
-87.3%
EPS YoY
+25.7%
Gross Margin
+92.4%
Op Margin
-32284.9%
Net Debt
-$68.26M
Current Ratio
3.07
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology